Large holder update, amended
Open the filing on sec.gov
Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2015
The companyfiscal 2025, as filed
Revenue$7.7M+640.7%
Net income-$465M-55.9%
Earnings per share$-4.95-34.1%
Operating cash flow-$378M-64.2%
Cash$102M-61.5%
Debtn/a
Shareholders’ equity$992M-25.1%
Shares, diluted94.1M+16.4%
Return on equity-46.9%
The recordfrom its filings
Filings in 2026107
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportFeb 26, 2026
Quarterly reportAug 3, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$6.7M
Insider buys, 12 months$0.00
Patents granted31
Filer categoryLarge accelerated filer
Trailing twelve months to Jun 2026Revenue $42.2MNet income -$502MCash from operations -$423Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Deregistration notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.